Everything below concerns circadian clock. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-08-16. Numbers and descriptions here follow the published literature rather than marketing material.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Research-use-only status in many markets |
| WADA status | Prohibited in sport | Generally listed as a non-approved substance |
| Detection technique | LC-MS/MS | Common for urine and blood analysis |
| Common alias | Stenabolic | Informal market nickname, not a pharmacopoeial name |
| Purity check | HPLC or LC-UV | Independent certificate of analysis is typical |
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
After stops in Helsinki and Moscow to smooth out Iraqi demands for a Middle-Eastern peace conference with the Soviet Union, Baker traveled to Syria to discuss its role with President Hafez Assad. Assad had a personal enmity towards Saddam, as "Saddam had been trying to kill him [Assad] for years." Harboring this animosity and impressed with Baker's initiative to visit Damascus (relations had been severed since the 1983 bombing of US barracks), Assad agreed to pledge up to 100,000 Syrian troops to the coalition. This was a vital step in ensuring Arab states were represented in the coalition. In exchange, Washington gave al-Assad the green light to wipe out forces opposing Syria's rule in Lebanon and arranged for weapons valued at a billion dollars to be provided to Syria, mostly through Gulf states. In exchange for Iran's support for the US-led intervention, the US promised Iran to end US opposition to World Bank loans to Iran. On the day before the coalition ground invasion, the World Bank gave Iran the first loan of $250m. Baker flew to Rome for a meeting with the Italians in which he was promised the use of military equipment, before journeying to Germany to meet with American ally Chancellor Kohl. Although Germany's constitution (brokered by the US) prohibited military involvement outside Germany's borders, Kohl committed a two billion dollar contribution to the war effort, and further economic and military support of coalition ally Turkey, and the transportation of Egyptian soldiers and ships to the Gulf.
== History == Before the development of the ELISA, the only option for conducting an immunoassay was radioimmunoassay, a technique using radioactively labeled antigens or antibodies. In radioimmunoassay, the radioactivity provides the signal, which indicates whether a specific antigen or antibody is present in the sample. Radioimmunoassay was first described in a scientific paper by Rosalyn Sussman Yalow and Solomon Berson published in 1960. As radioactivity poses a potential health threat, a safer alternative was sought. A suitable alternative to radioimmunoassay would substitute a nonradioactive signal in place of the radioactive signal. When enzymes (such as horseradish peroxidase) react with appropriate substrates (such as ABTS or TMB), a change in color occurs, which is used as a signal. However, the signal has to be associated with the presence of an antibody or antigen, which is why the enzyme has to be linked to an appropriate antibody. This linking process was independently developed by Stratis Avrameas and G. B. Pierce. Since it is necessary to remove any unbound antibody or antigen by washing, the antibody or antigen has to be fixed to the surface of the container; i.e., the immunosorbent must be prepared. A technique to accomplish this was published by Wide and Jerker Porath in 1966. In 1971, Peter Perlmann and Eva Engvall at Stockholm University in Sweden, and Anton Schuurs and Bauke van Weemen in the Netherlands independently published papers that synthesized this knowledge into methods to perform EIA/ELISA.
Diabetic hypoglycemia is a low blood glucose level occurring in a person with diabetes mellitus. It is one of the most common types of hypoglycemia seen in emergency departments and hospitals. According to the National Electronic Injury Surveillance System-All Injury Program (NEISS-AIP), and based on a sample examined between 2004 and 2005, an estimated 55,819 cases (8.0% of total admissions) involved insulin, and severe hypoglycemia is likely the single most common event. In general, hypoglycemia occurs when a treatment to lower the elevated blood glucose of diabetes inaccurately matches the body's physiological need, and therefore causes the glucose to fall to a below-normal level.
The presidents of the council were clearly the heads of government of the kingdom, holding the executive power that absolute monarchs had, but were restricted by the controlling power of the National Congress. With the advent of the Republic in the 5 October 1910 revolution, the head of government was renamed President of the Ministry (Presidente do Ministério). During this period the heads of government were under the strong power of the parliament and often fell due to parliamentary turmoils and social instability. With the 28 May 1926 coup d'état, and eventually, after the formation of the Estado Novo quasi-fascist dictatorial regime of António de Oliveira Salazar, the prime minister was again named President of the Council of Ministers, and was nominally the most important figure in the country. First Salazar and then Marcello Caetano occupied this post for almost 42 years. With the Carnation Revolution came the prime minister, which replaced the president of the council.
Sources: en.wikipedia.org
Anti-metabolites are a group of molecules that impede DNA and RNA synthesis. Many of them have a similar structure to the building blocks of DNA and RNA. The building blocks are nucleotides; a molecule comprising a nucleobase, a sugar and a phosphate group. The nucleobases are divided into purines (guanine and adenine) and pyrimidines (cytosine, thymine and uracil). Anti-metabolites resemble either nucleobases or nucleosides (a nucleotide without the phosphate group), but have altered chemical groups. These drugs exert their effect by either blocking the enzymes required for DNA synthesis or becoming incorporated into DNA or RNA. By inhibiting the enzymes involved in DNA synthesis, they prevent mitosis because the DNA cannot duplicate itself. Also, after misincorporation of the molecules into DNA, DNA damage can occur and programmed cell death (apoptosis) is induced. Unlike alkylating agents, anti-metabolites are cell cycle dependent. This means that they only work during a specific part of the cell cycle, in this case S-phase (the DNA synthesis phase). For this reason, at a certain dose, the effect plateaus and proportionally no more cell death occurs with increased doses. Subtypes of the anti-metabolites are the anti-folates, fluoropyrimidines, deoxynucleoside analogues and thiopurines. The anti-folates include methotrexate and pemetrexed. Methotrexate inhibits dihydrofolate reductase (DHFR), an enzyme that regenerates tetrahydrofolate from dihydrofolate. When the enzyme is inhibited by methotrexate, the cellular levels of folate coenzymes diminish.
Once a drug's bioavailability has been established it is possible to calculate the changes that need to be made to its dosage in order to reach the required blood plasma levels. Bioavailability is, therefore, a mathematical factor for each individual drug that influences the administered dose. It is possible to calculate the amount of a drug in the blood plasma that has a real potential to bring about its effect using the formula:
=== General References === ASTM F1416 Standard Guide for Selection of Time-Temperature Indicators Yam, K. L., "Encyclopedia of Packaging Technology", John Wiley & Sons, 2009, ISBN 978-0-470-08704-6 Taoukis, P. and T.P. Labuza. 2003. Time temperature indicators. In: Novel Food Packaging Techniques. R. Ahvenainen (ed.). Woodhead Publ., Cambridge, UK.
Sources: en.wikipedia.org
=== Beverage production === Pure cherry juice has a strong flavor and can have high acidity, so when produced commercially as a beverage product it is sometimes diluted with water to make it more palatable. Sugar syrup or dry sugar is sometimes added to the product when produced as a beverage. Mixtures of both hot-pressed and cold-pressed juices are sometimes used in the production of cherry juice beverages, which allows for a product that has a desirable coloration and flavor for consumers. Cherry juice is also produced as a carbonated beverage product.
In November 2025, United States President Donald Trump announced a deal with Novo to lower the costs of Ozempic, including monthly prices of about $245 for injectables and $149 for some oral versions for people on Medicare and Medicaid and for those who use his TrumpRx platform. In 2026, new obesity GLP-1 pills were launched, with patients getting their hands on them from Danish drugmaker Novo. Novo filed a federal lawsuit against Eli Lilly and Company in July 2026 in the District of New Jersey, alleging that Eli Lilly engaged in false advertising regarding its weight-loss and diabetes medications. The complaint accuses Lilly of misrepresenting comparative clinical data and omitting key information to gain an unfair advantage in the U.S. anti-obesity medication market.
The site is a megalithic construction dated to around 3000–2800 BC and composed of an open-air "corridor" about 40 meters long leading to two underground chambers that were supported during the site's construction by wooden pillars. Among the artifacts is a dagger with a blade made of rock crystal and an ivory handle decorated with 90 perforated discoid beads made of nacre. The main chamber contains human bodies and was covered with a red patina of cinnabar and decorated with sun motifs. The research by the University of Seville determined that during the winter solstice the sun was beaming for a few minutes through the entrance corridor, illuminating the funeral chamber and hitting a stele that represented the mother goddess. A Bayesian model based on 22 radiocarbon dates on human bone suggested that the use of Tholos de Montelirio started in 2875–2700 BC and ended in 2805–2635 BC.
Consequent to the Sino-Soviet split, the pragmatic China established politics of détente with the United States in an effort to publicly challenge the Soviet Union for leadership of the international Marxist–Leninist movement. Mao Zedong's pragmatism permitted geopolitical rapprochement and eventually facilitated President Richard Nixon's 1972 visit to China which subsequently ended the policy of the existence to Two Chinas when the United States sponsored the People's Republic of China to replace the Republic of China (Taiwan) as the representative of the Chinese people at the United Nations. In the due course of Sino-American rapprochement, China also assumed membership in the Security Council of the United Nations. In the post-Mao period of Sino-American détente, the Deng Xiaoping government (1982–1987) affected policies of economic liberalisation that allowed continual growth for the Chinese economy. The ideological justification is socialism with Chinese characteristics, the Chinese adaptation of Marxism–Leninism.
Sources: en.wikipedia.org
Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.
Anti-doping laboratories typically use LC-MS/MS to detect SR9009 or its metabolites in urine or blood. The exact assay depends on the laboratory and the testing program. Detection can be challenging because the compound may be rapidly metabolized and present at low levels.
Stenabolic is an informal nickname used in online fitness and research-chemical markets, not an official drug name. It likely references reported effects on endurance in rodent studies. The nickname does not imply approval or proven human benefit.
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.